This paper reviews and relates to the wider published literature a series of studies directed to the broad question of which antidepressant treatment is required for which kind of depressed patient. Adequate methodology requires comparisons with placebo and other active drugs, rather than analysis of single treatment groups, so that the magnitude of therapeutic benefit due to specific drug effects can be measured. Reasonably firm conclusions are now possible. Electroconvulsive therapy (ECT) is most effective in severely depressed patients, particularly those with delusions or retardation, and is superior to antidepressant drugs in such patients. Monoamine oxidase (MAO) inhibitors show some selectivity towards patients with anxiety or reversed functional shift symptoms, but this selectivity appears quite limited, and tricyclic antidepressants also benefit such patients. The possibility of other factors, not well reflected in clinical features, which determine consistency of response requires further investigation. Recent evidence has led to re-evaluation of the earlier view that tricyclic antidepressants were specifically indicated in endogenous depressions. They appear to be broad-spectrum antidepressants, with efficacy extending more widely into neurotic disorders, mixed anxiety depressions, anxiety disorders, and into the relatively mild non-endogenous depressions of general practice. of depressive illness.
Introduction
I am deeply conscious of the honour which the Association has done me in inviting me to deliver the annual guest lecture. The topic which I have chosen concerns the place of the antidepressants.
To be asked thus to address you encourages reversion to the long perspective. For some 25 years, interspersed with other kinds of studies, I have been undertaking studies of antidepressants aimed, in part, at prediction of response. An important question in most of these has been 'which antidepressant for which patient?'. I intend in this paper to look at some of these studies and relate them to other recently emerging literature. It appears to me that, although there are gaps, one can now draw some reasonably firm conclusions.
Earlier studies I shall skirt briefly over some earlier studies; they deserve no new exposure. The first (Paykel et al., 1968 ) was designed and started in 1963, while I was in my second year of registrar training at the Maudsley Hospital and in conjunction with colleagues at the same level: the original idea was due to Dr John Price. The study comprised a comparison of 3 weeks treatment with imipramine or chlorpromazine in doses of 200 mg/ day in depressed patients. We were intrigued by an early paper by Overall, Hollister and colleagues (Overall et al., 1964) in which imipramine and thioridazine showed little difference. Subsequently these authors (Overall et al., 1966) , using a new typology, found evidence that imipramine was superior in retarded depressives, thioridazine in anxious depressives, with no difference in hostile depressives. In our own study we could not demonstrate difference between * British Association for Psychopharmacology Annual Guest Lecture July 1988 July @ 1988 British Association for Psychophdrmacology the two drugs, or differentially responsive subgroups, although there was a hint of better response of retarded depressives to imipramine. The dose of chlorpromazine was low, and given the structural similarities between the two drugs, some overlap in the short term may not be too surprising. In the light of later evidence the treatment period was too short to demonstrate antidepressant effects clearly; the patients also tended to be rather chronic depressives who might be poor candidates for antidepressant effects. The study teaches a lesson; drug effects in depression are too weak and dependent on good trial design for one to be confident that they have been demonstrated without a placebo comparison.
A further look at tricyclics was possible during the period of about 5 years from 1966 to 1971 which I spent at Yale. In a series of classificatory studies we started with factor analyses and proceeded to a cluster analysis, at that time a new technique for psychiatry (Paykel, 1971;  Paykel, Prusoff and Klerman, 1971) .
Cluster analyses gave four readily interpretable groups: (1) psychotic depressives, a relatively small group of inpatients with clinical pictures characterized by retardation, anorexia, guilt, delayed insomnia, with about a third showing depressive delusions; (2) anxious depressives, a middle-aged group moderately severely ill with clinical histories characterized by longer illness and more recurrences, and symptom pictures with an admixture of anxiety, anergia, depersonalization, and obsessional symptoms; (3) hostile depressives were intermediate in most characteristics but showed hostility and self-pity out of proportion to their general severity-in replication analyses this group did not emerge as clearly; (4) young depressives with personality disorder consisted of young people relatively mildly depressed but with symptoms characterized by marked fluctuations, often in response to small concurrent environmental changes and with personal histories showing disturbances of social relationships suggestive of personality disorder.
In two successive samples treated with amitriptyline for 4-6 weeks (Paykel, 1972; Prusoff and Paykel, 1977) the worst outcome was in the anxious depressives and they were aberrant compared with the other three groups. In this classification there appeared to be three neurotic groups and one non-neurotic group. Two of the neurotic groups as well as the psychotic group responded well to the tricyclic and this was so even when severity and number of previous depressions were controlled for as covariates. The results using the typological prediction were considerably more illuminating than a parallel set of analyses using multiple regression analysis, the kind of analysis which had been used most commonly for prediction up till then (Paykel et al., 1973) . However, in our publications we noted the need for caution. There was no placebo group, and even though we tried by use of covariance analyses to rule out the confounding effect of chronicity, we could not be sure that the same results would not occur with other types of antidepressant drugs.
A further study, conducted at St George's in the early and mid-1970s, concerned the place of monoamine oxidase inhibitors (MAOIs) in therapy, an issue to which I will return more substantively. In an open predictor study (Paykel et al., 1979) depressives were treated with phenelzine for 4 weeks in a dose rising to 60 mg/ day. Significantly better response was found in both outpatients and day patients, rather than inpatients; in subjects scoring as atypical depressives in the diagnostic index of Robinson et al. (1974) ; in patients scoring as less severely ill and as showing anxiety features on factor analytically derived factors (Rassaby and Paykel, 1979) , and as hostile and agitated depressives on the typology described by Overall et al. (1966) , with anxious depressives, intermediate and retarded depressives showing poorly. These findings appeared consistent with the literature, which had previously been mainly clinical and descriptive, with few studies using statistical predictor analyses.
Requirements for demonstrating antidepressant specificity
What these studies aimed at showing was specificity of action of a particular antidepressant in producing response in specific kinds of patients within the clinical spectrum. We need to stop at this point to ask what is necessary to demonstrate this.
Although prediction of response may seem a straightforward idea, it is complex. In any patient who improves or recovers on treatment with an antidepressant, a number of different elements Fig. 1 . First, it may have been spontaneous, reflecting the natural history of the disorder. Second, many other treatment processes are also at work in a patient who receives an antidepressant, such as the perceived benefit of being able to ventilate one's problems to a sympathetic ear, the effect of coming into hospital with removal from stress and substitution of a supportive social environment, the effect of receiving an inert placebo.
The placebo group in drug trials controls for everything except the specific effects of the chosen antidepressant treatment. We do not know for certain the magnitude of spontaneous remission or non-specific treatment effects in depression. Spontaneous remission is probably more common than previously believed. It is clear from historical accounts that severe melancholia in the nineteenth century did in due course remit; the recognition of this remission contributed to Kraepelin's delineation of manicdepressive disorder from dementia praecox. Modern high prevalence and episode rates for mild depression in the community make it clear that much of this disorder remits without ever being recognized or treated. The limited evidence available, from a comparison of open and placebo antidepressant withdrawal (Paykel et al., 1975) would suggest that the effects of the placebo itself are in fact quite weak. However, the effects of other non-specific treatment factors are probably quite powerful. The specific effects of the drugs are not very large. In placebo-controlled trials in depression, as a rule only 20-30 per cent more recoveries occur on active treatment than on placebo, and relatively small proportions of the variance are accounted for.
When predictor analyses of response only examine the change in a group of subjects given the single treatment under investigation, improvement is an amalgam of the above factors, and it is not possible to say to which element significant predictors are related. If one wants to say that a certain treatment is indicated for a specific patient, one needs to focus on the specific effects of the treatment, that is, the magnitude of the difference between improvement on this drug and on placebo (Fig. 2) . One needs to show that these effects are greater in this patient group as opposed to those of placebo and of other treatments which might be given instead. The correct method is to make comparisons of response in similar patients receiving placebo or an alternative treatment. There are a number of statistical techniques which may be appropriate but probably the best is two-way analysis of variance (ANOVA), employing a design of treatments x subgroups where one seeks a significant interaction term indicating that differences between the two treatments are of different magnitude in different patient subgroups.
Viewed in this perspective the above studies (except the study of imipramine and chlor-Figure 2 Design for demonstrating selective effects of drugs on different patient types promazine) were limited. They followed an established line of research which had been adopted by many other investigators; they might drop useful hints, but could not be definitive. The question would always arise as to whether spontaneous remission and non-specific effects, or the specific effect of a very different treatment, might produce the same results.
From here on I will look more critically, from my own work and the work of others, at the general efficacy and any groups specifically responsive to three classes of treatment: electroconvulsive therapy (ECT), monoamine oxidase (MAO) inhibitors and tricyclic antidepressants.
Electroconvulsive therapy (ECT)
ECT is the oldest of the current antidepressant treatments, and although I have no personal data to present it is important to review briefly the literature as it sets a basis for comparison for the antidepressant drugs. First, what is its efficacy?
Among the most remarkable of studies have been the six recent blind comparisons of ECT and simulated ECT carried out in this country.
The first of the studies (Lambourn and Gill, 1978) showed virtually no benefits, and the Northwick Park study (Johnstone et al., 1980a) found effects that were less strong than might have been expected, but the remaining studies showed strong treatment effects among groups of relatively severely ill inpatients (Freeman, Basson and Creighton, 1978; West, 1981; Brandon et al., 1984; Gregory, Shawcross and Gill, 1985) .
In studies examining who responds best, ECT was the target of the earliest predictor studies and most of these have been concerned with the psychotic-neurotic dichotomy, giving clearcut evidence that psychotic depressives show a better response. The earliest study was that of Hobson (1953) who constructed a predictor index in which the items were very similar to those distinguishing psychotic and neurotic depressives, although he did not adopt that terminology. Since then, a moderately large number of studies have come to similar conclusions (Paykel, 1979) , the main dissenting study being that of Abrams, Fink and Feldstein (1973) . All these studies were without control groups and did not conform to the design I have advocated. One study which did do so was the Massachusetts collaborative study (Greenblatt, Grossen and Wechsler, 1964) . Breakdown by diagnosis showed, among manicdepressives (bipolar and unipolar in modern terminology) 78 per cent markedly improved on ECT as opposed to 37 per cent on placebo; for involutional psychotics the figures were 85 per cent and 25 per cent; for psychoneurotic depressive reaction, 77 and 83 per cent. In addition, the Northwick Park study (Clinical Research Centre, 1984) ; in subsequent analyses found the superiority of active ECT was mainly in patients with depressive delusions.
Published studies of ECT almost exclusively involve inpatients in the severely ill range. Among such patients, ECT does appear more effective than tricyclic antidepressants and MAO inhibitors. There have in fact been quite a number of non-blind comparative trials with random assignment (Paykel, 1979) . Among nine comparisons with tricyclic antidepressants, six found ECT better overall, and three studies found equal drug effects. Among comparisons with MAO inhibitors, the superiority is even more striking, with ECT being more effective in six of seven studies. No study has found drug treatment more effective overall than ECT, although two have suggested more rapid effects from the drugs, contrary to the usual clinical view.
MAO inhibitors (MAOIs)
Views on the specific indications for MAO inhibitors first emerged clearly from the work of Sargant and his colleagues at St Thomas' Hospital. West and Dally (1959) described a syndrome of atypical depression. There have been many subsequent papers.
When we came to look over the literature we were impressed that there were three different meanings which had been used by different authors when referring to atypical depression (Paykel et al., 1983 ). The first one was that of marked anxiety and phobic symptoms, either accompanied by depression, or assumed to have some relation to an underlying depression as indicated, for instance, by diurnal variation. This would include the influential views of Tyrer (1976) that MAO inhibitors are 'delayed psychostimulants' indicated for agoraphobia, anxiety neurosis, anergia and mixed anxiety depressions rather than pure depressions.
The second meaning is what Pollitt (1965) describes as reversed functional shift, that is, depression with a diurnal pattern of evening worsening, insomnia of early rather than late kind or increased sleep, increased appetite and weight, all directly opposite to the physiological changes said to characterize endogenous depression. In the United States Klein and colleagues (Liebowitz et al., 1984) assign principal importance to these features. A third meaning of atypical depression seems to be that of non-endogenous depression in general. This is a wider meaning than the usual implication of the specific subgroup. Also in the United States the series of studies carried out by Robinson, Nies and Ravaris have employed a diagnostic index for typical and atypical depression (Robinson et al., 1974) which corresponds to this view.
These three meanings may identify different groups of patients. In a sample of outpatient depressives we collected a large amount of data relevant to diagnosis including specific diagnoses on many different subclassificatory systems (Paykel et al., 1983) . We examined the relationships between different diagnostic systems using separate criteria for the presence of marked anxiety symptoms, reversed functional shift and non-endogenous depression. We found reasonable consistency of different measures within each single concept, although the reversed functional shift features related to each other less well. However, the three separate concepts related poorly and tended to select quite different patients. As shown in Fig. 3 , among 128 subjects classified as atypical on at least one of the three definitions, only eight satisfied all three, and even pairwise concordance was modest. We had to conclude that the concept of atypical depression was imprecise. It would better to specify which aspect was to be emphasized.
The best evidence on the efficacy of monoamine oxidase inhibitors is for phenelzine. Among fourteen controlled trials against placebo in depression (Paykel, 1979; Liebowitz et al., 1988) seven have shown the drug clearly superior to placebo, three have been doubtfully positive, and four failed to show drug superior to placebo. This is clearly better than chance expectation that 1 in 20 would show 5 per cent significance (assuming that all negative studies are published), but it is less impressive than for ECT or for tricyclic antidepressants. There are also a number of posi- Paykel et al. (1983) tive studies in phobic disorders. Several early major trials which showed efficacy of tricyclic antidepressants failed to show this for MAO inhibitors (Greenblatt, Grosser and Wechsler, 1964; Medical Research Council, 1965; Raskin et al., 1974) . The much less widespread use of MAO inhibitors is partly due to this, but it is mainly due to the troublesome interactions and the necessity for dietary precautions which makes these drugs much less easy to use, and much less acceptable to either the average patient, or to the general practitioner.
In the fourteen studies there was not a very strong relationship between response and defined subtype, but there was a clear relationship to treatment setting. All except one of the studies showing drug-placebo differences have been in outpatient samples, with the one positive study in inpatients using very high doses of 90 mg/day. All the negative studies have been carried out on inpatients. Studies in day patients or mixed patients have tended to be equivocal.
The most likely explanation would be that this reflects diagnostic subtype, since outpatients are likely to be less severely ill and more neurotic in symptom pattern. Some reevaluation may, however, be needed here since most of the inpatient trials were early studies, using doses and treatment periods that were relatively low by modern standards.
Our open predictor study of phenelzine (Paykel et al., 1979) was really a pilot study for a more thorough controlled trial of phenelzine, amitriptyline and placebo carried out in outpatient depressives and mixed anxiety depressives, and aimed particularly at exploring subtypes differentially responsive to one or other of the classical types of antidepressant. In this study 131 subjects were treated for 4-6 weeks with either phenelzine, rising either to 60 mg or 75 mg/day, amitriptyline 150-187.5 mg/day, or placebo. Overall we found clear drug effects for both drugs with surprisingly little difference between them. As shown in Fig. 4 , on a depression measure, the total depression score from the clinical interview for depression (Paykel, 1985) , the three groups started at closely similar levels, but by 2 weeks the placebo group were responding less well. By 6 weeks both drug treatment groups were clearly and significantly superior to placebo. There was little difference between them, with amitriptyline minimally superior to phenelzine on ratings of depression. The pattern was very similar in anlyses of anxiety only in this case phenelzine was minimally superior to amitriptyline. The important finding was that both drugs were much superior to placebo. The differences between them, although in the pre-dicted direction, were very slight .
More relevant than symptom rating is the question as to whether different subgroups of patients respond differently. In order to examine this we undertook a series of two-way analyses of covariance with various subclassifications as the second factor with drug treatment in the design and incorporating a number of outcome measures . The subgroups were predominantly based on the three different views of atypical depression.
Using subclassifications based on presence or absence of additional anxiety symptoms, there were some interactions, although they were not very strong. The typical pattern was that phenelzine was clearly superior to placebo in those depressives with an admixture of anxiety, but not in those without anxiety. However, amitriptyline was superior to placebo in both groups. Figure 5 shows an example of this interaction which is, however, considerably less marked in some of the other analyses.
The two other views of atypical depression, presence of reversed functional shift and nonendogenous depression in general, were examined in a similar way. Neither of these classifications gave significant interactions with drug response.
There are techniques for comparing regression Figure 4 Severity of depression and anxiety in (a) outpatient depressives and (b) mixed anxiety depressives over 6 weeks on phenelzine, amitnptyhne or placebo. Modified from . equations from single treatment groups, and we also computed separate regression equations for phenelzine and for amitriptyline groups and compared them using initial symptoms to predict response (Bhat, Rowan and Paykel, 1984 ). They were not significantly different. This illustrates that regression techniques can be used for the similar purposes.
Overall the findings of this study suggested a weak selectivity of MAO inhibitors in patients showing anxiety rather than lacking it. However, the effect was very weak. In general, the drugs appeared rather similar in their action. In this mildly ill, neurotic and somewhat anxious group of depressives, usually not regarded as showing much benefit from tricyclic antidepressants, amitriptyline was clearly superior to placebo, and did not show any particular selectivity.
The general weakness of differences between tricyclics and MAO inhibitors in clinical terms is
consistent with other recent studies. Ravaris et al. (1980) found only weak differences between amitriptyline and phenelzine. As in our study, there was a tendency for phenelzine to have more effect on anxiety measures. Davidson et al. (1986) , analysing patients from a number of studies, found only weak differences between patients responding to the two classes of drug. There was a tendency for better effects of MAO inhibitor rather than tricyclic where a precipitant was present and, contrary to expectation, in the absence of agoraphobia. When separate analyses were carried out in the two sexes some further predictors were found, but these were not consistent between the sexes.
Liebowitz, Klein, Quitkin and colleagues from the New York State Psychiatric Institute have, however, found stronger differences (Liebowitz et al., 1988) . Selecting patients on the basis of their definition of atypical depression, depending particularly on reversed functional shift and on mood reactivity, they found 71 per cent of patients responding to phenelzine, 50 per cent to imipramine, and 28 per cent to placebo. Examining subgroups within this selected sample, they unexpectedly found that superiority of both phenelzine and imipramine to placebo was largely confined to patients with spontaneous panic attacks and/or hysteroid dysphoric features. Davidson et al. (1988) in a comparative trial of isocarboxazid and placebo found the drug superior to placebo in major but not minor depressives, and significantly more effective in depression classified as endogenous or its DSM III equivalent, melancholia, by various diagnostic criteria. Somewhat inconsistent with this, the drug was more effective than placebo in atypical depression with reversed functional shift and in Overall's subtypes of anxious and hostile depression. It was no better than placebo in atypical depression without reversed functional shift or in BPRS retarded and agitated depression. In general, these two very recently published studies do suggest a little more selectivity for reversed functional shift than the earlier studies, and some convergence with presence of anxiety, but still the overall impression is of weak differences. It remains possible that there is some other variable, rather than clinical symptomatic subtype, which predicts a better response to MAO inhibitors. Most clinicians are used to having some patients under their care who seem to respond only to this class of drug. Supporting this view, Pare and Mack (1971) , comparing outcome in patients who in successive episodes had received antidepressants of the same or of different types, found a significant tendency for consistent response in the same direction, that is good or bad, with the same class of drug and inconsistent responses across different kinds of drug. They also found some consistency in responses among relatives. This was a small study which needs repeating, but does support the view that there are some specific response factors which might be related to biochemical variables only weakly reflected in symptom pattern.
Tricyclic antidepressants
From the point of view of efficacy, tricyclic antidepressants are well-evaluated drugs. A useful review was published by Morris and Beck (1974) . Surveying the limited selection of tricyclic antidepressants then available in the United States, they found 93 comparative trials against placebo. Among these, 61 showed drug superior to placebo and 32 failed to do so. There will be more positive studies of additional drugs by now, so the evidence for efficacy is impressive. Why then the negative studies? Some will have been due to poor trial technique, such as short treatment periods, low doses and unsatisfactory outcome measures. However, some of the negative studies undoubtedly reflect the limited benefit obtained from these drugs, mentioned earlier.
The view that tricyclics are particularly effective in endogenous depression has an impressive lineage, going back as early as the initial studies.
However, a critical look at the controlled trials published in the 1960s suggests that, although the effect may have been a little better in endogenous depressives, there was evidence of benefit in neurotic depressives (Paykel, 1979) . Certainly there have been many controlled trials, in which a tricyclic was superior to placebo in samples characterized as neurotic or reactive (Ball and Kiloh, 1959; Wittenborn et al., 1962; Uhlenhuth and Park, 1964; Covi et al., 1974; Friedman, 1975) .
More recent findings regarding delusional depression also present a problem. Although they are associated with psychotic/endogenous depression a number of reports have indicated that delusions predict a poor response to tricyclic antidepressants and a better response to ECT (Paykel, 1979) . It would appear that the most severe endogenous or psychotic depressives do not respond very well to tricyclics. If anything there is a curvilinear relationship in which the best response is shown by patients with the endogenous symptom pattern but moderate severity. Rao and Coppen (1978) found the best response to amitriptyline in patients with scores in middle range on the Newcastle Scale for endogenous depression.
There is increasing evidence that tricyclics are superior to placebo in neurotic states other than depression. Marks (1983) reviewed a number of studies showing tricyclics superior to placebo in obsessional neurosis and in agoraphobia. The obsessional studies depend mainly on one drug, clomipramine, with a more serotoninergic action, but the studies in agoraphobia have employed more standard drugs. Marks argued that the effect was only apparent where depression was present, but others have disputed this. Two important studies including a spectrum of anxious and depressed patients have not received the attention they deserve. Johnstone et al. (1980b) treated such patients with amitriptyline, diazepam or placebo. Amitriptyline was consistently superior to placebo while diazepam showed only weak effects, even in patients with predominant anxiety. Kahn et al. (1986) carried out a similar study with imipramine, chlordiazepoxide or placebo with similar findings.
These studies would suggest that earlier studies including our own (Paykel, 1972) finding a poor response to tricyclics in presence of anxiety are only partly correct. Although the disorder tends not to have a very good outcome, tricyclics do convey some therapeutic benefit.
Tricyclic antidepressants in milder depressions in general practice
We have recently been examining effects of tricyclics in mild depression by means of a controlled trial in general practice, in which setting the majority of depressed patients in this country are treated; only between one-sixth and onetenth are referred to psychiatrists. Most tricyclic antidepressant prescribing is in general practice and in 1985 more than 7.3 million tricyclic prescriptions were filled by retail pharmacies in Great Britain. However, evidence for the efficacy of antidepressants depends mainly on studies of patients of moderate or greater severity treated as psychiatric outpatients or inpatients.
Among the few placebo controlled trials of tricyclics conducted in general practice in this country, Porter (1970) found imipramine 75-150 mg no better than placebo in a 3-week study, but Thomson et al. (1982) found amitriptyline clearly superior to placebo. In Australia, Blashki, Mowbray and Davies (1971) found amitriptyline 150 mg/day, but not 75 mg/day, superior to placebo, and in the United States Rickels et al. (1970) have found antidepressants effective in several studies. Because conditions of general practice differ between countries, different kinds of patients may have been treated in these studies.
In a preparatory survey study, we examined the characteristics of depressives treated by general practitioners (Sireling et al., 1985a and b; Freeling et al., 1985) . Three samples of depressives were studied: patients newly started on a tricyclic antidepressant; patients recognized by the general practitioner as depressed enough to require treatment but not given a tricyclic; and Research Diagnostic Criteria (RDC) major depressives not recognized by the general practitioner and detected by screening and subsequent interview. The majority of antidepressant-treated depressives were cases on the PSE-CATEGO system, but many were at the threshold level. About half were RDC probable or definite major depressives, another quarter RDC minor depressives, and the remainder received another diagnosis, predominantly of an anxiety state. Among depressives receiving other treatment, only about a fifth were major depressives with 31 per cent minor depressives and the remaining 50 per cent receiving other diagnoses, most commonly of anxiety disorders. At least as many major depressives failed to be recognized by the general practitioner as were recognized; they tended to show less overt depressive symptoms, which were more likely to be related to physical illness. As in a few earlier studies, when compared with antidepressanttreated psychiatric outpatients, the general practice depressives were considerably less severely ill, with fewer depressive symptoms, shorter illness, less primary and less endogenous depression (see Table 1 ). This study established a strong case for a controlled trial in general practice to establish efficacy and, particularly, subgroups responding preferentially to a tricyclic. We therefore undertook a placebo-controlled trial of amitriptyline Hollyman et al., 1988) ; 141 depressives identified in general practice and satisfying the Research Diagnostic Criteria Sireling et al. (1985b) . Only 53 of 95 antidepressant-treated general practice patients satisfied criteria for major depressive disorder.
(RDC) (Spitzer and Endicott, 1978) for major or minor depression were treated double-blind for at least 4 weeks, and in most cases 6 weeks, with amitriptyline or placebo. The mean doses in the 4th and 6th week were approximately 120 mg/day. As shown in Fig. 6 , mean initial total scores on the 17-item Hamilton rating scale for Depression were closely similar and a little below 15, confirming the relative mildness of the sample. Differences started to appear surprisingly earlier Figure 6 Severity of depression over 6 weeks in general practice depressives treated with amitriptyline or placebo. From Paykel et al. (1988) and at 2 weeks hqà reached significance. By 6 weeks highly signifi ant differences had appeared on a wide variety of outcome measures with amitriptyline impressively superior to placebo.
It has sometimes been argued that the effects of tricyclic antidepressants in mildly depressed patients in general practice are largely due to sedation and effects on sleep. We therefore examined a wide set of symptom ratings, particularly from the Hamilton rating scale and the clinical interview for depression (Paykel, 1985) . Individual symptom ratings on which drug was significantly superior to placebo at the end of the study included, in addition to insomnia, a variety of core symptoms of depression, particularly depressed mood, guilt, pessimism and hopelessness, and depressed appearance. The effect was clearly a true antidepressant one and it was also shown on a number of global measures.
In order to examine for responsive subgroups we carried out a series of two-way analyses of covariance with initial level as covariate and using as the second factor a variety of classifications from the literature. We sought interactions which would indicate differential drugplacebo differences. We analysed five relatively global outcome measures and since this involved a comparatively large number of analyses we only accepted them for further examination where at least two of the five outcome measures in a subgroup showed significant interactions at the 5 per cent level or better.
Significant interactions were relatively few, indicating fairly strong and consistent drug effects across most subgroups. Subgroups failing to give rise to interactions included demographic variables, history of chronicity, and, most impressively, endogenous versus neurotic depression defined on a number of different criteria in terms of symptoms or precipitant stress. Only in one area, severity, were there interactions, and even here they were relatively weak, only reaching 5 per cent significance in two of the five analyses, although there were consistent effects at around the 10 per cent level on the other outcome measures.
These two subgroups, based on RDC major versus minor depression and on severity on the Hamilton Scale, showed an illuminating pattern which is shown in Fig. 7 . The distinction between RDC major and minor depression depends mainly on the number of concomitant symptoms of depression which are present. For minor Figure 7 Severity of depression at baseline and 6 weeks in Research Diagnostic Criteria (RDC) major and minor depressives. From Paykel et al. (1988) depressions, less in severity, drug and placebo groups both improved but remained closely similar. For major depressions, starting with more severe, the amitriptyline group improved considerably more than the placebo group to reach similar levels at the end of the study to the minor depressives. Active drug was beneficial to major but not to minor depressives.
On the initial Hamilton score we divided the sample into three groups: the most mild, with Hamilton scores below 13; those intermediate, with initial scores 13-15; and the relatively more severe comparable with psychiatric outpatients. Figure 8 Seventy of depression at baseline and 6 weeks in groups defined by initial levels of 6-12, 13-15, and 16-24 on 17-item Hamilton Scale. From Paykel et al. (1988) We found a very similar pattern in outcome to that based on major and minor depression (Fig.  8) . Here, however, it was only the very mildly ill patients who showed no benefit from the active drug; there were considerable drug placebo differences for the two other patient groups, and again the effect was to produce final scores from amitriptyline close to those of the mildly ill.
There appears to be a level which the milder patients reach spontaneously, that represents improvement rather than no change, and this is as much as can be achieved in 6 weeks. The effect of the active drug is to move the patients in the higher ranges of what is still a relatively mild disorder down to this floor level.
These findings are consistent with another study in the literature. Stewart et al. (1983) treated 64 depressives not scoring over 18 on the Hamilton Scale with either desipramine or placebo. Patients fitted criteria for RDC major, intermittent or minor depression, with only a few of the last included. The drug was superior to placebo in major but not intermittent depression; although numbers were somewhat low there was no convincing evidence of better response in any subtype of major depression. Patients with initial Hamilton scores of 14-18 showed that the drug was superior to placebo, those with Hamilton scores of 13 or under did not. Later analyses (Stewart et al., 1985) confirmed that the antidepressant was superior to placebo in DSM III major depression, both with and without melancholia, but not in dysthymic disorder. It also appeared effective in patients with panic attacks.
Conclusions
To conclude, I have summarized a rather lengthy series of studies all directed, at least in part, to the question of whether specific antidepressant treatments are indicated for specific groups of patients. I have not reviewed some newer data of my own and of other investigators examining the serotonin reuptake inhibitors, for, although there are some hints, pointing I think in the direction of better effects in anxiety, one cannot yet reach a definitive answer concerning them. We are currently carrying out a placebo-controlled trial of a different class of putative antidepressant, the GABA-agonist fengabine, but the study is not yet completed and we do not yet know what the findings will be. I have tried to focus this paper on areas where reasonably firm conclusions can be reached. I have not dealt with psychological and social approaches to treatment since this is inappropriate here. I would emphasize nevertheless that these treatments are valuable. Cognitive therapy and the briefer psychotherapies have been well evaluated in controlled trials and there is no doubt that they produce considerable benefit. The practical place and specific indications for cognitive therapy are important questions at present, with intriguing and suggestive evidence of relapse prevention, and the picture is likely to become clear in the next few years.
Perhaps the first conclusion to be drawn is that modern antidepressant treatments are effective. Prior to the introduction of ECT, although the earlier studies indicate that patients did improve and recover, the spontaneous course might be quite a long one, and inpatient acute wards were fairly accustomed to long hospitalization in persisting psychotic depressive states. Nowadays, even if we do need better treatments and relapse remains a problem, the majority of depressives show considerable improvement within a few weeks or, at the most, months of starting treatment. Resistant depression is unusual.
Second, although ECT has not been much evaluated in mildly ill patients, all the pointers would suggest that it is most effective in severely depressed patients, particularly those with retardation or depressive delusions. Here it clearly is superior to antidepressant drugs. Whether ECT or tricyclic and similar antidepressants should be the first choice is a moot point on which there is room for disagreement. The common view in this country is that where retardation or delusions are prominent it is best to start with ECT rather than delaying with an antidepressant and then having to use it later.
Monoamine oxidase (MAO) inhibitors are more problematic. Overall, they seem a little less effective than tricyclics, but really it is the interactions that markedly limit their use, and it will not be until truly interaction-free MAO inhibitors are developed that their place expands; they do have a very legitimate place as secondchoice drugs. Modern evidence suggests that the patients who respond to them are more like those responding to tricyclic antidepressants than has hitherto been thought. The evidence does suggest that they are somewhat more selective than the tricyclics, and does tend to confirm the early observations of astute clinicians that this selectivity lies more in the area of anxiety symptoms or reversed functional shift; but even here tricyclics are also superior to placebo. The situation regarding inpatients and MAO inhibitors still needs re-evaluation with modern doses and longer treatment periods; many clinicians, including myself, use them in severe resistant depression with good results, particularly when combined with lithium. They are a good first choice for those patients who have been demonstrated to respond preferentially to them in the past. In the empirical evidence for consistency of response, irrespective of clinical picture, there is some biochemical clue which requires further study.
It is for the tricyclics that greater re-evaluation is required. The earlier view that these were specifically indicated for endogenous or psychotic depressive inpatients seems to have been misleading. While they are often effective in inpatients, they appear to be less so in the most severely ill and psychotic. Moreover, their effectiveness extends much more widely than at first thought, into anxiety, panic and phobic disorders. Recent studies including our own, show that they produce benefit extending into a surprisingly mild range of depression, although there is a threshold which is still above normality. The tricyclics appear to be truly broad-spectrum antidepressants which are justifiably the mainstay of modern antidepressant pharmacotherapy.
